Since mutations in exon 2 of MED12 are found also in the majority (50–80%) of uterine leiomyomas [9–13], Schwetye et al. [9] concluded that “smooth muscle tumors in pelvic/retroperitoneal sites are subject to the same mutational changes as those of uterine myometrium, and [that] these mutations may precede the gross or histological development of a leiomyoma” [9]. This evidence concerns the gene MED12 and uterine corpus leiomyoma.